Paraoxonase-2: A potential biomarker for skin cancer aggressiveness
| Autor: | Eleonora Salvolini, Annamaria Offidani, Lucrezia Togni, Anna Campanati, Davide Sartini, Guendalina Lucarini, Tiziana Bacchetti, Gianna Ferretti, Corrado Rubini, Roberto Campagna, Monica Emanuelli, Elisa Molinelli, Veronica Pompei, Valerio Brisigotti, Monica Mattioli-Belmonte |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Skin Neoplasms Clinical Biochemistry 030204 cardiovascular system & hematology Biochemistry Breslow Thickness 03 medical and health sciences 0302 clinical medicine medicine Mitotic Index Humans Basal cell carcinoma Neoplasm Invasiveness 030212 general & internal medicine Lymph node Melanoma Aged Aged 80 and over business.industry Aryldialkylphosphatase Cancer General Medicine Middle Aged medicine.disease Immunohistochemistry Tumor Burden Mitochondrial respiratory chain medicine.anatomical_structure Carcinoma Basal Cell Cancer research Female Lymph Nodes Skin cancer business |
| Zdroj: | European journal of clinical investigationREFERENCES. 51(5) |
| ISSN: | 1365-2362 |
| Popis: | Background Cutaneous neoplasms include melanoma and non-melanoma skin cancers (NMSCs). Among NMSCs, basal cell carcinoma (BCC) represents the most common lesion. On the contrary, although accounting for less than 5% of all skin cancers, melanoma is responsible for most of cutaneous malignancy-related deaths. Paraoxonase-2 (PON2) is an intracellular enzyme exerting a protective role against production of reactive oxygen species within mitochondrial respiratory chain. Recently, a growing attention has been focused on exploring the role of PON2 in cancer. The aim of this study was to investigate the diagnostic and prognostic role of PON2 in skin neoplasms. Materials and methods 36 cases of BCC, distinguished between nodular and infiltrative lesions, as well as 29 melanoma samples were analysed by immunohistochemistry to evaluate PON2 protein expression. Subsequent statistical analyses were carried out to explore the existence of correlations between intratumour enzyme levels and clinicopathological features. Results Results obtained showed PON2 overexpression in BCCs compared with controls. In particular, distinguishing between less and more aggressive tumour forms, we found no significant differences in enzyme levels between nodular BCCs and controls. Conversely, PON2 expression was significantly higher in infiltrative BCCs compared with controls. Moreover, the enzyme was strongly upregulated in melanoma samples with respect to controls. Interestingly, PON2 levels were positively correlated with Breslow thickness, Clark level, regression, mitoses, lymph node metastases, primary tumour (pT) parameter and pathological stage. Conclusions Reported findings seem to suggest that PON2 expression levels could be positively related with tumour aggressiveness of both BCC and melanoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text